Expert Reviews in Molecular Medicine: http://www.expertreviews.org/
DOI: 10.1017/S1462399407000208; 9 January 2007
Maria P. de Leon, Jennifer M. Rolland and Robyn E. O'Hehir (2007) The peanut allergy epidemic: allergen molecular characterisation and prospects for specific therapy. Expert Rev. Mol. Med. Vol. 9, Issue 1, DOI: 10.1017/S1462399407000208

The peanut allergy epidemic: allergen molecular characterisation and prospects for specific therapy

Maria P. de Leon ^a1, Jennifer M. Rolland ^a1 and Robyn E. O'Hehir ^{a1 a2 c1}

^a1 Department of Immunology, Monash University, Melbourne, Victoria 3004, Australia.

^a2 Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Victoria 3004, Australia.

^c1 Corresponding author: Robyn E. O'Hehir, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Commercial Road, Melbourne, Victoria 3004, Australia. Tel: +61 3 9276 2251; Fax: +61 3 9207 1692; E-mail: robyn.ohehir@med.monash.edu.au

Peanut (Arachis hypogaea) allergy is a major cause of food-induced anaphylaxis, with increasing prevalence worldwide. To date, there is no cure for peanut allergy, and, unlike many other food allergies, it usually persists through to adulthood. Prevention of exposure to peanuts is managed through strict avoidance, which can be compromised by the frequent use of peanuts and peanut products in food preparations. Conventional subcutaneous-injection allergen immunotherapy using crude peanut extract is not a recommended treatment because of the risk of severe side effects, largely as a result of specific IgE antibodies. Consequently, there is an urgent need to develop a suitable peanut allergen preparation that can induce specific clinical and immunological tolerance to peanuts in allergic individuals without adverse side effects. This requires detailed molecular and immunological characterisation of the allergenic components of peanut. This article reviews current knowledge on clinically relevant peanut allergens, in particular Ara h 1, Ara h 2 and Ara h 3, together with options for T-cell-reactive but non-IgE-binding allergen variants for specific immunotherapeutic strategies. These include T-cell-epitope peptide and hypoallergenic mutant vaccines. Alternative routes of administration such as sublingual are also considered, and appropriate adjuvants for delivering effective treatments at these sites examined.

Full text online (purchase or subscribe through Cambridge Journals Online)

| home | search | glossary | links | sitemap | contact |

Expert Reviews in Molecular Medicine © Cambridge University Press ISSN 1462-3994 (Disclaimer and copyright)
Editorial Office: Centre for Applied Research in Educational Technologies (CARET), 1st Floor, 16 Mill Lane, Cambridge, CB2 1SB, UK. Tel: +44 (0)1223 765 375; Fax: +44(0)1223 765 505; E-mail: ermm@caret.cam.ac.uk